Stocks · News reference
Inhibrx Biosciences Says FDA Accepts BLA Seeking Approval Of Ozekibart In Patients With Conventional Chondrosarcoma; PDUFA Goal Date Set For April 14, 2027
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jun 15, 2026, 1:19 PM
- Checked
- Jun 15, 2026, 1:25 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Inhibrx Biosciences Q2 EPS $(2.34) Beats $(2.39) Estimate
Read original at benzinga8-K filing — Inhibrx Biosciences, Inc. (INBX)
Filed: 2026-08-13 AccNo: 0002007919-26-000044 Size: 271 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar